Menu

USC President Steps Down in Wake of Gynecologist Scandal

An uproar over the university’s handling of sexual misconduct accusations led to C.L. Max Nikias’s resignation.  

May 29, 2018
Sukanya Charuchandra

C.L. Max NikiasFLICKR, DANIEL HINTON FOR DEPARTMENT OF DEFENSEFollowing a backlash over alleged sexual misconduct by a gynecologist at the school health center, C.L. Max Nikias, president of the University of Southern California (USC), stepped down late last week (May 25).

“We have heard the message that something is broken and that urgent and profound actions are needed,” Rick Caruso, a member of the USC Board of Trustees, says in a statement.

Nikias has been in office since 2010, leading the Los Angeles-based university through a period of enormous growth as it benefitted from a $6 billion donation. However, over the past few years, a series of scandals have gripped the establishment. The university’s response to the allegations against George Tyndall, the campus gynecologist for nearly 30 years, was the final nail in the coffin for Nikias’s tenure, according to The New York Times.

Following several complaints from students and staff spanning decades and an ensuing investigation that found Tyndall ’s behavior constituted sexual harassment, he was offered money to resign. Several women have filed lawsuits against Tyndall, according to USA Today, and reporting by the Los Angeles Times has sparked criticism from students, alumni, and faculty over the past few weeks. A letter asking Nikias to resign had garnered almost 500 signatures from faculty by Friday.

“We’re at a real crossroads for the university and this is the first step in starting over,” Ariela Gross, a law professor who led the faculty effort, tells The New York Times.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.